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Abstract: Objective: Tumor necrosis factor-beta (TNF-β), as an inflammatory mediator that has
been shown to promote tumorigenesis, induces NF-κB. Natural multi-targeted agent resveratrol
in turn shows anti-inflammatory and anti-cancer properties. Epithelial-to-mesenchymal transition
(EMT) allows cancer cells to turn into a motile state with invasive capacities and is associated
with metastasis and development of cancer stem cells (CSC). However, TNF-β-induced EMT and
the anti-invasion mechanism of resveratrol on CRC are not yet completely understood. Methods:
We investigated the underlying molecular mechanisms of resveratrol on TNF-β/TNF-βR-induced
EMT and migration of CRC cells (HCT116, RKO, SW480) in monolayer or 3D alginate cultures.
Results: TNF-β, similar to TNF-α, induced significant cell proliferation, morphological change, from
an epithelial to a spindle-like mesenchymal shape with the formation of filopodia and lamellipodia
associated with the expression of EMT parameters (elevated vimentin and slug, reduced E-cadherin),
increased migration/invasion, and formation of CSC in all CRC cells. Interestingly, these effects
were dramatically decreased in the presence of resveratrol or anti-TNF-βR with TNF-β co-treatment,
inducing biochemical changes to the mesenchymal-epithelial transition (MET), with a planar cell
surface and suppressed formation of CSC cells. This was associated with a significant increase
in apoptosis. Furthermore, we found that resveratrol suppressed TNF-β-induced NF-κB and
NF-κB-regulated gene biomarkers associated with growth, proliferation, and invasion. Finally,
TNF-βR interacts directly with focal adhesion kinase (FAK) and NF-κB. Conclusion: These results
suggest that resveratrol down-regulates TNF-β/TNF-βR-induced EMT, at least in part via specific
suppression of NF-κB and FAK in CRC cells.
Keywords: resveratrol; colorectal cancer; TNF-β (lymphotoxin α); epithelial-to-mesenchymal-transition
(EMT); NF-κB
1. Introduction
In industrialized countries, colorectal cancer is the third most common cancer diagnosed and
ranks second in terms of mortality [1]. It is estimated that by the year 2035, mortality rates for
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colon cancer would have increased by 60% [2]. The main reason for colon cancer-related mortality is
resistance to current standard chemotherapeutic treatments, resulting in high incidence of metastatic
recurrence [3,4]. This highlights the need for novel therapeutic approaches, which may enhance
chemosensitivity and suppress metastatic recurrence and thus improve overall survival rates.
Chronic inflammation presents a critical component of tumor initiation and progression [5].
The nuclear factor “kappa-light-chain-enhancer” of activated B-cells (NF-κB) is an important
transcription factor for the immune defense and is involved in regulating cell proliferation and
apoptosis [6,7]. In several cancers, NF-κB is constitutively activated, stimulating pro-inflammatory
cytokines’ activation and chemokines, promoting proliferation and suppressing apoptosis [8,9].
Hereby, activation of pro-inflammatory mediators in the tumor microenvironment plays a major role
in modulating communication between the tumor cells and their environment, eventually promoting
invasion and migration of tumor cells [10]. In particular, NF-κB-dependent activation of members
of the Tumor-Necrosis-Factor-superfamily has been identified as being critically involved in this
process [9]. Indeed Tumor Necrosis Factor-alpha (TNF-α) and its stimulating role in cancer has been
well studied [11], but the role of its closest homologue TNF-β (alias Lymphotoxin-α) remains to
be elucidated.
We and others have previously shown that TNF-β can, like TNF-α, modulate proliferation,
survival, invasion, migration, and colony formation in colorectal and ovarian cancer [12,13].
Indeed, similar to TNF-α, TNF-β stimulates an inflammatory cascade in cancer cells and investigations
on ovarian tumors have shown that TNF-β is over-expressed in cancer cells and associated
fibroblasts [12]. It has previously been shown that TNF-β may activate canonical and non-canonical
NF-κB pathways [14–17] and signals through the lymphotoxin-β receptor (LTβR) [18]. Interestingly,
induction of NF-κB by binding of TNF-β to LTβR has previously been shown to activate cell death in
HT29 adenocarcinoma cells [19].
Evidence has shown that inflammation in the tumor microenvironment acts as a potent promoter,
converting cells into a motile state by stimulating epithelial-to-mesenchymal-transition (EMT) in
cancer cells [20]. The cancer cell’s loss of stationary properties, cell–cell and cell–matrix bound
properties, is associated with loss of inter- and extracellular junctions and remodeling of cell–matrix
interaction [21]. A major marker for the loss of epithelial properties is E-Cadherin suppression,
leading to a loss of adherence and polarized organization of epithelial cells [22–24]. Furthermore,
EMT is known to promote the formation of cancer stem cells [25,26] and activate drug resistance [27].
Interestingly, the pathways leading to EMT and malignancy of cancer cells are tightly regulated by
multiple mediators at the epigenetic and post-translational level [24].
Resveratrol (trans-3,5,4’-Trihydroxystilben), a natural polyphenol, has been associated with a
variety of different medicinal effects, like anti-inflammatory and anti-neoplastic properties [28–30].
In cancer, resveratrol has been shown to up-regulate intercellular junctions and focal adhesion
molecules, block EMT, suppress inflammatory pathways, and initiate apoptosis [30–32].
We have previously shown that TNF-β-induced CRC cell (HCT116, HCT116R) migration from
3D-alginat cultures and TNF-β has increased chemoresistance in CRC cells to 5-FU. Furthermore,
resveratrol could significantly chemosensitize CRC cells to 5-FU in a TNF-β-promoted inflammatory
tumor microenvironment [13]. Very recently, we have reported that a TNF-β signaling pathway is
involved in proliferation in CRC cells and that resveratrol down-regulates the TNF-β-mediated
inflammatory response by suppressing NF-κB promotion, which regulates the proliferation of
tumor cells [33]. In addition, it has been reported that the EMT is a crucial mechanism of cancer
progression [25,26], however, whether TNF-β induces migration and EMT in various colorectal cancer
cells has not yet been evaluated and needs to be further investigated. Therefore, we performed a
comparative morphological, ultrastructural, and biochemical study to examine the modulatory effect
of resveratrol on EMT and migration caused by TNF-β/TNF-β-receptor signaling, using three different
CRC cell lines. In the present report, we provide evidence that resveratrol suppresses the TNF-β
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signaling pathway via the TNF-βR to decrease EMT, further highlighting its significant implications
for inflammation-induced tumor promotion, particularly in CRC.
2. Materials and Methods
2.1. Antibodies, Cytokines, and Chemicals
Anti-CXCR4 (CXC-Motiv-Chemokinreceptor 4) was acquired from Abcam PLC (Cambridge, UK).
Anti-CD133, -ALDH1, and -CD44 were purchased from Antibodies-online. Anti-phospho-specific
p65 (NF-κB) and anti-MMP-9 were from R&D Systems (Heidelberg, Germany). Anti-E-cadherin,
anti-vimentin, and anti-slug were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-FAK was purchased from Becton Dickinson (Heidelberg, Germany). Monoclonal antibodies
to Ki-67 and secondary antibodies used for fluorescence labelling were purchased from Dianova
(Hamburg, Germany). Anti-β-actin, alginate, resveratrol, and Staphylococcus aureus bacteria were from
Sigma–Aldrich Chemie (Munich, Germany). TNF-β, TNF-α, anti-TNF-β-receptor, and anti-TNF-β
were purchased from eBiosciences (Frankfurt, Germany). In addition, TNF-β and TNF-α, were kindly
provided by Genetech, Inc. (South San Francisco, CA, USA) [34]. Secondary antibodies for
Western blotting were from Millipore (Schwalbach, Germany) and gold particle-conjugated secondary
antibodies were from Amersham (Braunschweig, Germany). Resveratrol was dissolved in ethanol as
stock and stored at –20 ◦C. Epon was from Plano (Marburg, Germany).
2.2. Cell Lines
The human CRC cell lines (HCT116, SW480) used in this study, were from the European Collection
of Cell Cultures (Salisbury, UK). The RKO cell line was from the American Type Culture Collection
(ATCC). A whole cell culture growth medium, supplemented with 10% FCS, was prepared and cells
cultured as previously described in detail [30].
2.3. Experimental Design
Human CRC cell (HCT116, SW480, and RKO) monolayer cultures were washed three times with a
serum-starved medium (3% FCS) and incubated for 1 h with the same medium. CRC cells were either
left untreated or treated with 10 ng/mL of TNF-β or TNF-α alone for 12 h, or pretreated with 5 µM
resveratrol by itself or 5 µM resveratrol for 4 h, followed by co-treatment with 10 ng/mL of TNF-β or
TNF-α and 5 µM resveratrol for 12 h.
For the invasion assay, serum-starved HCT116, RKO, and SW480 CRC cells in alginate bead
culture were left untreated, treated with 5ng/ml or 10ng/mL TNF-β or TNF-α, 5 µM resveratrol, or the
combination of resveratrol and TNF-β or TNF-α for 14 days. In an additional approach, HCT116, RKO,
and SW480 cells were left untreated, treated with TNF-β, resveratrol, TNF-β and resveratrol, or treated
in suspension with an anti-TNF-β-receptor (0.1, 1, 10, 20 µg/mL) for 15 min, and then transferred to
the alginate, followed by co-treatment with or without 10 ng/mL of TNF-β or resveratrol for 14 days.
These investigations were performed in triplicate and the findings are presented as mean values from
three independent investigations.
2.4. Immunofluorescence Investigations
CRC cells (HCT116, RKO, and SW480) in monolayer cultures were treated as described above
and were subjected to immunofluorescent labelling for slug, vimentin, and E-cadherin as previously
described in detail [30]. In a second approach, untreated CRC cells were investigated for TNF-β
and TNF-βR immunofluorescence labeling. Briefly, after blocking with 1% BSA/PBS, cells were
incubated with primary antibodies, diluted 1:80 in 1% BSA/PBS overnight at 4 ◦C, washed with PBS,
and incubated with secondary antibodies diluted at 1:100 for 1.5 h. Finally, cells were counterstained
with a DAPI (4, 6-Diamidino-2-phenylindole, Sigma, Munich, Germany) nuclear stain and visualized
through a fluorescent microscope (Leica, Germany). All investigations were performed at least in
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triplicate and the percentage of positively labelled cells was quantified by counting 600–800 cells in
10 microscopic fields.
2.5. Three Dimensional Alginate Culture
Cultivation of CRC cells in three-dimensional in vitro culture was performed as alginate bead
culture, as previously described [30,32,35]. The alginate tumor microenvironment culture provides an
in vivo close environment and is extremely suitable for studying early events in tumorigenesis.
2.6. Invasion and Colony Forming Assay
The influence of resveratrol and/or TNF-β/TNF-α on invasion and colony formation capacity of
CRC cells was investigated in alginate bead culture, as previously described [30,35]. Cells that had
migrated through the alginate matrix and formed newly adhered colonies on the bottom of the petri
dishes were labeled with toluidine blue and quantified by counting all colonies under a microscope.
Every investigation was repeated in triplicate, data were compared to the control, and statistically
significant values with p < 0.05 are shown by one asterisk (*); p < 0.01 by two asterisks (**).
2.7. Cell Viability Investigation from Alginate Culture
Cell viability of CRC cells in alginate bead culture was assessed by applying the MTT method as
previously stated [32]. Briefly, serum-starved CRC cells were left untreated or treated, as described
above, and then cultivated for 14 days in alginate cultures. To retrieve CRC cells from the alginate,
beads were dissolved in 55 mM sodium citrate solution for 20 min, as described previously [36].
Finally, viability of CRC cells was determined using a revelation 96-well multiscanner plate ELISA
reader (Bio-Rad Laboratories Inc. Munich, Germany), by measuring the Optical Density at 550 nm
(OD550). The investigation was performed in triplicate and the data are provided as mean values with
standard deviations from three independent experiments.
2.8. Ultrastructural Investigations
Ultrastructural investigations of monolayer cultures were performed to evaluate the effect of
resveratrol and/or TNF-β on CRC cells, as previously stated [35]. CRC monolayer cultures were fixed
for 1 h in Karnovsky fixative, followed by post-fixation in 1% OsO4 solution. After dehydration in
an ascending alcohol series, cells were embedded in Epon and cut ultrathin with a Reichert-Jung
Ultracut E (Darmstadt, Germany). Ultrathin sections were contrasted with uranyl acetate/lead
citrate and evaluated with a transmission electron microscope (Jena, Germany) or a Jeol 1200 EXII
(Akishima Tokyo, Japan). For statistical evaluation of apoptotic cells, 100 cells from 25 microscopic
fields were counted manually and all obtained data were compared to the control and statistically
significant differences were highlighted with p < 0.05 (*); p < 0.01 (**).
2.9. Pre-Embedding for Ultrastructural Immunoelectron Microscopy
Monolayer cultures of CRC cells were left untreated or treated, as stated above. The effect of
resveratrol and/or TNF-β on EMT marker E-Cadherin and vimentin in CRC cells was investigated
by an ultrastructural immunoelectron pre-embedding technique, as previously described [32].
Briefly, cells in suspension were incubated with a primary antibody for 15 min and diluted 1:50 in a
cell culture medium at an ambient temperature (AT). After washing with PBS three times, cells were
incubated with 10 nm goat anti-rabbit gold-conjugated secondary antibodies (diluted 1:50 in cell
culture medium) for an additional 10 min at AT. After fixation with 2% glutaraldehyde for 5 min,
followed by 1% OsO4 solution for 5 min, cells were dehydrated in a series of ethanol concentrations and
finally embedded in Epon. Ultrathin sections were prepared and examined using a Zeiss transmission
electron microscope (Jena, Germany) or a Jeol 1200 EXII (Akishima Tokyo, Japan).
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2.10. Immunoblotting Investigations
HCT116, RKO, and SW480 CRC cells in alginate bead culture were left untreated or treated,
as described above. Cell lysates for immunoblotting investigations were extracted from CRC cells in
alginate bead cultures, as previously described [30,35]. The investigations were performed in triplicate,
and β-actin was applied as a control and to normalize the protein quantities.
2.11. Immunoprecipitation Assay
Immunoprecipitation investigations were performed to elucidate the relationship between
TNF-β-receptor and endogenous signaling interactions with focal adhesion kinase (FAK) or with NF-κB,
as previously described [37,38]. CRC cells were either left untreated or treated with TNF-β (10 ng/mL)
in suspension for 10 min and then transferred to the alginate for 3 days. For immunoprecipitation,
cell extracts were incubated with 25 µl rabbit and mouse IgG serum and Staphylococcus aureus bacteria
to pre-clear samples. They were incubated with antibodies against TNF-β-receptor in a wash buffer
(0.1% Tween 20, 150 mM NaCl, 50 mM Tris-HCl, pH 7.2, 1 mM CaCl2, 1 mM MgCl2, and 1 mM PMSF)
for 2 h at 4 ◦C, followed by 30 min incubation with Staphylococcus aureus bacteria. Finally, obtained
immune complexes were washed with a lysis buffer. Samples were reduced with 2-mercaptoethanol,
subjected to SDS-PAGE under reducing conditions, and were blotted onto a nitrocellulose membrane,
using a transblot apparatus (Bio-Rad, Munich, Germany).
2.12. Statistical Analyses
The data were expressed as the mean ± SE and statistical significance between the groups
was compared by one-way, two-way, or a three-way ANOVA, and the Wilcoxon–Mann–Whitney
test. Each investigation was performed at least three times. A p-value < 0.05 was considered
statistically significant.
3. Results
The goal of this paper was to investigate the effect of resveratrol on TNF-β-induced tumorigenesis
of human colorectal cancer cells (CRC) through regulation of EMT. We used three well-described CRC
cell lines (HCT116, RKO, and SW480) in a monolayer, as well as a 3D alginate tumor microenvironment
culture to answer this question. The amount of ethanol or DMSO used in our study had no suppressive
effect on the viability of cells.
3.1. TNF-β Induces EMT in CRC Cells and Resveratrol Reverses That
Since EMT plays an important role in tumor invasion and metastasis [39], we first investigated
whether TNF-β with or without resveratrol leads CRC cells to EMT cell morphology by light
microscopy. HCT116, RKO, and SW480 cells in monolayer cultures were treated as delineated
in Materials and Methods. As indicated in Figure 1, in all three CRC cell lines, control cultures
and monolayer cultures treated with resveratrol showed typical colonies (arrows) with an overall
epithelial cell shape and tight cell-to-cell contacts (Figure 1A). Interestingly, treatment with resveratrol
significantly enhanced cell-to-cell contact, and the majority of cells formed a more rounded cell
shape (Figure 1A). However, after treatment with 10ng/mL TNF-β or TNF-α for 12 h, all three
CRC cells changed their shape from a typical epithelial to a spindle-like fibroblast-like appearance.
The cell-to-cell contacts became detached and cells showed a more mesenchymal shape with less
colony origin (Figure 1A). By contrast, in all cell lines, co-treatment with resveratrol and TNFs led
markedly to an epithelial cell cluster with increased cell-to-cell contacts (Figure 1A).
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 Figure 1. Impact of resveratrol on TNF-β-induced epithelial-to-mesenchymal transition (EMT) and
EMT-related proteins in CRC cells (HCT116, RKO, SW480). CRC cells in monolayer culture were either
left untreated (Co) or treated with 5µM resveratrol (Res), 10 ng/mL TNF-β, or 10ng/mL TNF-α for 12 h,
or cells were pre-treated with resveratrol (5µM) for 4 h, followed by co-treatment with 10ng/mL TNF-β
or 10ng/mL TNF-α for 12 h. (A) Cell phenotype changes associated with EMT, as demonstrated
in phase contrast images. Cell colonies (arrows). Scale bar = 100 µm. (B) Immunoblotting of
cell lysates was performed for E-cadherin, vimentin, and slug. The housekeeping protein β-actin
served as an internal loading control. (C) Immunolabeling was done with primary antibodies for
E-cadherin, vimentin, and slug, followed by incubation with rhodamine-coupled secondary antibodies.
All experiments were performed at least in triplicate and quantification of positively labelled cells was
done by counting 600–800 cells from 10 microscopic fields. All data were compared to the control and
statistically significant values with p < 0.05 were designated by (*) and p < 0.01 were designed by (**).
Original magnification, 600×. Scale bar = 30 nm.
To confirm the morphological results described above and to show more precisely the identity of
the epithelial-to-mesenchymal-transition (EMT) biomarker, whole cell extracts were probed for slug,
vimentin, and E-cadherin expression. Western blotting analysis showed that in CRC cells, TNF-β,
similar to TNF-α, reduced the epithelial marker (E-cadherin) and elevated the mesenchymal markers
(vimentin) and EMT-related transcription factor (slug) on the protein level, and resveratrol alone or in
co-treatment with TNFs significantly decreased vimentin and slug levels and increased E-cadherin
expression (Figure 1B).
Furthermore, to confirm the morphological and western blotting results that the CRC cells
underwent EMT by TNF-β treatment, which is inhibited by resveratrol, we investigated the
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expression of EMT markers and the EMT-related transcription factor by immunofluorescence analysis.
The untreated control cells demonstrated a minimum amount of E-cadherin, vimentin, and slug
expression. On the other hand, the expression of vimentin and slug was markedly elevated,
and E-cadherin was reduced in the presence of TNF-β alone (Figure 1C). Treatment of CRC cells
with resveratrol alone or in combination with TNF-β clearly demonstrated the inhibition of vimentin,
the transcription factor slug, and increasing of E-cadherin expression (Figure 1C). Overall, these results
demonstrate that all three CRC cell lines underwent EMT after TNF-β-treatment and that resveratrol
can inhibit this induction, inducing biochemical and functional changes towards to MET. Furthermore,
the suppression of EMT by resveratrol was not cell type specific, because EMT was inhibited in HCT116,
RKO, and SW480 cells.
3.2. Resveratrol Suppresses CRC Cell Malignancy by Modifying the Ultrastructure of the Cell Surface Protein
It is known that EMT is the first step in increasing cancer malignancy and the cell membrane
ultrastructure plays a crucial role in cell adhesion and invasion [22–24]. To further evaluate the
impacts of TNF-β with or without resveratrol on EMT in CRC cells, we examined the alteration
on the cell surface ultrastructure by transmission electron microscopy. As shown in Figure 2A, a–c,
untreated control cells showed epithelial morphological capacities of cell proliferation and aggregation.
Cells were more round to oval and grew in close clusters, with several small microvilli and cell
surface processes, a well-developed rough endoplasmic reticulum, Golgi apparatus, and mitochondria,
which indicate the maintenance of metabolic active cells (Figure 2A, a–c). Furthermore, CRC cells
treated with TNF-β, like TNF-α, clearly exhibited alteration on the cell surface structures associated
with increased length of the membrane extensions, microvilli, and long filopodia, reminiscent of
mesenchymal-like morphology (Figure 2A, d–f). In the presence of resveratrol alone, the CRC cells
revealed an epithelial morphology, planar surface, and, additionally, degenerative changes in cell
morphology. Repeated vacuoles appeared, as well as swollen and degenerated cell organelles and cell
nuclei containing more condensed heterochromatin and this caused almost complete cell degradation
and apoptosis (Figure 2A, g–i). Resveratrol by itself or co-treated with TNF-β, like TNF-α, caused a
transformation to an epithelial shape. Cells showed an epithelial cell surface with almost a planar
surface and apoptosis (Figure 2A, j–l). Quantification of apoptotic cells supported these findings.
Overall, these findings suggest that TNF-β promotes cell morphology alteration and significant
spreading on the cell surface, whereas the resveratrol signaling pathway induces an MET phenotype
and apoptosis, and slows down cell spreading in all three CRC cells.
We next examined the epithelial morphology induced through resveratrol and cell surface proteins
of the MET marker (E-cadherin) in all CRC cells by immunoelectron microscopy. HCT116, SW480,
and RKO cells were either untreated or treated, as described before, in a monolayer culture. As
demonstrated in Figure 2B, a–c, untreated control cells showed low amounts of the epithelial protein
(E-cadherin) (Figure 2B, a–c) diffusely distributed on the round HCT116, SW480, and RKO cells.
Furthermore, the TNF-β-treated cells showed diminished E-cadherin expression (Figure 2B, d–f).
By contrast, resveratrol induced a round shape with a substantially high expression of E-cadherin
(Figure 2B, g–i) and this was seen predominantly on the planar cell body between the cells in CRC cell
lines (Figure 2B, g–i). Treatment of CRC cells with resveratrol and/or co-treated with TNF-β showed
overexpression and increased levels of E-cadherin (Figure 2B, j–l). Taken together, these findings
supported the results in Figures 1 and 2A, that resveratrol induces expression of the adhesion epithelial
marker (E-cadherin) in spite of TNF-β treatment in all colon cancer cell lines stimulating biochemical
and functional alterations towards MET.
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Figure 2. Electron microscopic observation of cell-surface and cell-morphology in CRC cells after treatment
with TNF-β or/and resveratrol. HCT116, RKO, and SW480 were cultured in a monolayer culture and
were untreated (a–c), or treated with TNF-β (d–f) or TNF-α with resveratrol (g–i) alone, or with TNF-β
and co-treated with resveratrol (j–l), or TNF-α and co-treated with resveratrol, as described above and
investigated with a transmission electron microscope. (A) Untreated control (Co) tumor cells showed
a planar surface and moderate microvilli (arrows) on the cell surface (a–c). By contrast, treatment with
TNF-β or TNF-α resulted in alteration of cell surface ultrastructure and cells contained abundant, long
microvilli and filopodia-like structures on the cell surface (d–f). By contrast, treatment of tumor cells
with resveratrol alone (g–i) or co-treated cells with resveratrol and TNF-β (j-l) displayed only a few
microvilli, with an overall planar surface. Tumor cells became rounded and the nucleus contained more
heterochromatin, multiple vacuoles, and swelling of cell organelles like mitochondria. Apoptotic bodies
(arrowheads) and cell lysis (*) was visible. a–l: Magnification, 5000x. Scale bar = 1 µm. Insets: Scale
bar = 0.09 µm. To quantify mitochondrial changes (MC) and apoptosis in tumor cells, 100 cells from
25 microscopic fields were counted. Values were compared with the control and statistically significant
values with p < 0.05 were designated by (*) and p < 0.01 were designated by (**). (B) Effect of resveratrol on
E-cadherin expression in CRC cells shown by immunoelectron microscopy. Immunogold labeling (arrows)
is observed at the plasma membrane of CRC cells with antibodies against E-cadherin. Scale bars = 0.2 µm.
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3.3. Resveratrol Suppresses TNF-β-Promoted Migration, Colon Cancer Stem Cell Markers, NF-κB Activation,
and NF-κB-Regulated Gene Products Involved in Proliferation and Metastasis
To examine whether resveratrol has a modulatory effect on CRC cell invasion and migration
promoted by TNF-β, alginate invasion tests were performed. As shown in Figure 3A, the three CRC
cell lines showed significantly amplified cell migration with TNF-β treatment, similar to TNF-α,
and resveratrol suppressed this clearly, compared with the corresponding control. Quantification of
invasive and adhered colonies confirmed these findings.
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Figure 3. Impact of resveratrol and/or TNF-β on cancer stem cell (CSC) migration, expression of
CSC marker, NF-κB, and NF-κB-related proteins involved in proliferation and metastasis. CRC cells
were incubated in alginate culture and treated as described in M terial nd Methods. (A) Migrated
colonies were labelled with toluidine blue and the number of migrated colonospheres was counted
after 14 days in culture. Exp rim ntal d a were compared with the control and statistically
significant values with p < 0.05 were designated (*) and p < 0.01 were designated (**). (B) Whole
cell lysates of alginate beads were made, and immunoblotting was don with antibodies against
CD133, CD44, and ALDH1. Results of immunoblot analysis in three different CRC cell lines presented
are representative of three individual experiments. The housekeeping protein β-actin was used as a
positive loading control. Densitometric analysis of protein expression, as shown with immunoblotting,
was done in triplicate. Values were compared with the control and statistically significant values
with p < 0.05 were shown as (*) and p < 0.01 were shown as (**). (C). Whole cell lysates of alginate
beads were fractionated and immunoblotted with anti-p-NF-κB, anti-MMP-9, anti-CXCR4, anti-Ki-67,
and anti-β-actin. Densitometric assessment was done for phospho-p65, MMP-9, CXCR4, and Ki-67.
* p < 0.05, ** p < 0.01. β-actin was used as a loading control in all experiments.
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Since it was demonstrated that TNF-β, as cytokine, induced the formation of cancer stem cells
(CSCs) in HCT116 cells [13], we further investigated whether TNF-β was able to stimulate the formation
of CSCs in HCT116, SW480, and RKO cells like TNF-α in 3D alginate cultures and whether resveratrol
could modulate the formation of these CSCs. The HCT116, SW480, and RKO cells were cultured in
an alginate-beads microenvironment and then treated as described in Materials and Methods. In the
alginate, cells formed colonospheres, and we tested the expression of CD133, CD44, and ALDH1 by
immunoblotting analysis (Figure 3B). As shown in Figure 3B, consistent with the migration assay
findings, CD133, CD44, and ALDH1 protein expression in tumor control culture cells was moderate
(Figure 3B). Contrary to that, TNF-β, like TNF-α, clearly stimulated the expression of CSC markers
(CD133, CD44, and ALDH1) in all CRC cell lines. Furthermore, resveratrol by itself and/or with
TNF-β and/or with TNF-α promoted marked down-modulation of CD133, CD44, and ALDH1 in all
CRC cells, compared to the control (Figure 3B). Overall, these findings suggest that TNF-β, like TNF-α,
promotes CRC cell activation, progression, and metastasis, increasing CSCs and thereby enhancing
the malignancy of the cancer cells. Resveratrol suppresses this, explaining the noticeable targeting
of resveratrol for CSCs. Densitometric analysis of immunoblot experiments shows down-regulation
of CSC biomarkers in all three CRC cells treated with either TNF-β or TNF-α and/or resveratrol,
demonstrating that it is one of the multitargeting cellular and principle mechanisms of resveratrol for
tumor suppression (Figure 3B).
A large body of literature indicates that NF-κB is a crucial transcriptional mediator of
pro-inflammatory cytokines that promote proliferation, invasion, malignancy, and EMT of cancer
cells [40–43]. To further elucidate the underlying pathway, how resveratrol, a multitargeting
agent, acts on TNF-β-induced tumorigenesis in CRC cells, we investigated NF-κB phosphorylation
and activation of NF-κB-regulated gene products, which are involved in proliferation, invasion,
and metastasis. The alginate cultures of all CRC cells were either untreated or treated, as indicated
in Materials and Methods. As demonstrated in Figure 3C, the results of immunoblotting showed
that resveratrol down-regulated TNF-β-activation of NF-κB and NF-κB-promoted gene proteins
MMP-9, Ki-67, and CXCR4, all factors relevant for promoting tumorigenesis, and these were confirmed
by quantitative densitometry. Taken together, these findings highlight that specific inhibition of
TNF-β-induced NF-κB signaling pathways by resveratrol, at least partially, is one of the crucial
anti-tumorigenic mechanisms of resveratrol during tumorigenesis.
3.4. Endogenous Demonstration of TNF-β and of TNF-βR on the CRC Cell Membrane
We found that TNF-β was a potent cytokine for promoting the malignancy of cancer cells.
To further validate these findings, we also investigated the role of TNF-βR on the migration of all CRC
cells. We then investigated the endogenous expression of TNF-β and TNF-βR in different CRC cell
lines by immunofluorescence labeling and immunoblotting analysis. Interestingly, in control cultures,
immunofluorescence labeling demonstrated that all three CRC cell lines had a basal expression of
TNF-β and of TNF-βR protein (Figure 4A). Overall, these results demonstrate that TNF-βR expression
is associated with a specific receptor for TNF-β-induced malignancy in cancer cells. More interestingly,
we have shown that TNF-β, like TNF-α, activated the expression of TNF-βR, and that resveratrol
markedly inhibited either TNF-β- or TNF-α-promoted TNF-βR proteins (Figure 4B). Taken together,
these data demonstrate that specific inhibition of TNF-β-promoted TNF-βR pathways in CRC cells by
resveratrol, at least partially, is one of the multitargeting mechanisms of anti-tumorigenic properties
of resveratrol.
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Figure 4. Expression of TNF-β receptor in three CRC cell lines and resveratrol suppressing their
expression. (A) CRC cells in monolayer cultures were immunolabeled with primary antibodies for
TNF-β and TNF-β recepto (TNF-βR), followed by incubation w th rhodam ne-coupled secondary
antibodies and counterstaining with DAPI to visualize cell nuclei. Original magnification, 400x. Scale
bar = 30 nm. (B) CRC cell lines in monolayer cultures were untreated (Co) or treated, as described
above. Whole cell lysates were fractionated and immunoblotted with antibodies against TNF-βR and
β-actin. β-actin was used as a loading control in all experiments.
3.5. Anti-TNF-βR or Resveratrol Down-Modulates TNF-β-Promoted Proliferation, Invasion, and Colony Formation
Results from Figures 2 and 3 suggest the potential of TNF-β for enhancing survival and metastasis
of CRC cells and that resveratrol down-modulates that. Next, we wanted to know whether anti-TNF-βR
plays a role in the treatment of CRC alone and/or with TNF-β, and what specific mechanisms
participate. HCT116, SW480, and RKO (Figure 5A) cells in alginate were either untreated or treated,
as indicated in Materials and Methods, and an MTT assay was performed. The results indicate
that TNF-β stimulated CRC cell viability and proliferation, which was significantly inhibited by
resveratrol. Interestingly, TNF-βR suppressed cell proliferation in the presence or absence of TNF-β in
a dose-dependent manner. In addition, marked inhibition in proliferation of CRC cell lines was shown
in an anti-TNF-βR and resveratrol combinational treatment (Figure 5A). We probed further the cell
invasion ability of three CRC cell lines, using alginate invasion assay. CRC cell lines in the alginate
matrix were treated as indicated in Materials and Methods for 14 days and a migration assay was
performed. All CRC cell lines have shown high invasion and colony formation levels, while CRC cell
invasion and colony formation was markedly suppressed by anti-TNF-βR treatment dose-dependently,
compared to controls (Figure 5B). Taken together, these results indicate clearly, for the first time,
that TNF-βR, at least in part, is one of the essential signaling molecules on tumor cells in cytokine
(TNF-β)-promoting tumorigenic effects in CRC cells.
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Figure 5. Resveratrol or anti-TNF-βR blocks TNF-β-induced proliferation, migration, and colony
formation of CRC cell lines. (A) Suppression of the proliferation of CRC cells by resveratrol or
anti-TNF-βR, as shown by MTT. CRC cells in alginate culture were untreated (Co) or treated,
as described in Materials and Methods. e results we e provided by at least three individual
experiments. Values were compared with the control, and statistically significant values with p < 0.05
were designated by an asterisk (*) and p < 0.01 were designated by two asterisks (**). (B) Suppression of
CRC cell migration and motility by anti-TNF-βR. The igration-bas d cell motility alginate culture was
used to define the relative cell motility of the three CRC cell lines, as described above. After 14 days,
migrated cells developed colonies on the bottom of petri dishes and they were fixed and labelled with
toluidine blue. Typical alginate culture dishes indicated reduced colony formation by anti-TNF-βR
dose-dependently, with or without TNF-β.
3.6. TNF-β-Promoted TNF-βR Expression Interacts with FAK and NF-κB in CRC Cells
We further investigated the metastasis effect of TNF-β and TNF-βR on proteins that contribute
to cancer metastasis. Cytoskeleton remodeling, cell adhesion, chemotaxis and focal adhesion
kinase (FAK)-signaling pathways, and NF-κB were associated with regulating tumor cell survival,
invasiveness, and metastasis [42–46]. We next executed co-immunoprecipitation assays to determine
the possible physical interplay of TNF-βR and FAK and/or NF-κB in CRC cell lines in alginate cultures.
All three CRC tumor cells were either untreated or treated with TNF-β (10ng/mL) in suspension for
10 min, and then transferred to alginate for three days. Cell lysates were immunoprecipitated with
antibodies against TNF-βR, followed by immunoblotting with p-FAK or with p-NF-κB antibodies.
As shown in Figure 6, we found in all CRC cells in TNF-β-treated cultures an obvious strong
co-immunoprecipitation of the TNF-βR protein with the p-FAK, or with the p-NF-κB protein
(Figure 6). In untreated control cultures, marginal TNF-βR co-immunoprecipitation with the p-FAK or
p-NF-κB protein was observed (Figure 6). Collectively, these results further suggest TNF-β-promoted
TNF-βR-FAK/-NF-κB complex formation during tumorigenesis and it may be one of the important
downstream pathways for TNF-β/TNF-βR, leading to malignancy and metastasis in CRC cells.
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Figure 6. Association of T -βR proteins with focal adhesion kinase (FAK) or NF-κB in CRC cells.
CRC cells were untreated (Co) or treated with TNF-β (10ng/mL) in suspension for 10 min, and then
transferred to the alginate beads for three days. Whole cell lysates were immunoprecipitated (IP)
with anti-TNF-βR. Finally, the immunoprecipitates were separated by SDS-PAGE and analyzed by
immunoblotting (IB), using anti-p-FAK (A) and anti-p-NF-κB (B). Densitometric assessment of protein
expression, as shown by immunoblotting, was done in triplicate. The original extracts were tested with
an antibody o β-actin, a a loading contr l. Data were compared with the control and statistically
significant data with p < 0.05 were designated an asterisk (*) and p < 0.01 were designated two asterisks
(**). IgH = immunoglobulin heavy chain.
4. Discussion
Previous reports suggested that inflammatory cytokines produced in the cancer microenvironment,
such as TNF-α, act as a major promotor and modulator of tumorigenesis through activation
of EMT and different signaling pathways, including NF-κB [47–50]. However, the role of the
pro-inflammatory cytokine TNF-β during tumorigenesis is still poorly understood and requires
further investigation. Moreover, natural compounds as multitargeted agents have the ability to inhibit
cancer cell proliferation, survival, EMT, invasion by regulating focal adhesive molecules, cell surface
proteins, apoptosis-associated genes, and signal transduction pathways [51–53]. Our group has shown
previously that resveratrol induces apoptosis and down-modulates focal adhesion kinase (FAK) and
inflammatory transcription factors, such as NF-κB, and NF-κB-promoted gene protein expression in
CRC cells [13,30,54]. The goal of this investigation was to determine whether TNF-β as a cytokine could
serve as a promoter for migration and EMT in various CRC cells and to determine the down-modulating
impact of resveratrol on invasion and EMT induced by TNF-β.
In this paper, we showed that TNF-β, similar to TNF-α, stimulated distinctive morphological
and molecular changes from epithelial to fibroblast-like mesenchymal phenotypes (EMT) with the
formation of filopodia and lamellipodia, and this was accompanied by EMT factors (increased vimentin
and EMT-specific transcription factor slug, decreased E-cadherin) in all three CRC cell lines. We also
found, with immunoblotting and immunofluorescence evaluation, clear TNF-β-induced expression
of CSC-specific biomarkers (CD133, CD44, ALDH1) in all three CRC cells. These findings underline
the essential impact of the tumor-promoting inflammation factor TNF-β as a dominant agent in
promoting and supporting EMT and development of CSCs, thus, cancer progression and metastasis
in CRC. In addition, these data are in accordance with findings from other studies, indicating that
tumor cells change their morphology and phenotype from epithelial to higher cell motility and
malignancy-mesenchymal phenotypes, and synthetize EMT-specific factors during tumorigenesis [23],
accompanied by down-modulation of cell adhesion molecules (E-cadherin) and stimulation of
vimentin, slug, and matrix metalloproteinase expression [55]. Furthermore, previous reports have
demonstrated that the pro-inflammatory cytokine, TNF-α, is able to stimulate EMT in a various range
of tumor cells [56]. Additionally, there have been greater amounts of TNF-α mRNA found in CRC
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cells, compared to normal epithelial colon cells [57]. Interestingly, it has been shown that EMT is an
adequate triggering signal for CSC development and activation in malignancy and metastasis of cancer
cells [25]. These data are in further accordance with previous studies, which have reported that EMT is
crucial for tumor cell motility, migration, metastasis, and the CSC phenotype. Thus, epithelial tumor
cells dissociate from adjacent cells and invade the surrounding tissue [58–60].
In correlation with the consideration that TNF-β as an inflammatory cytokine is a key decisive
factor in cancer promotion, we showed that resveratrol, like anti-TNF-βR with TNF-β co-treatment,
significantly decreased cell migration and EMT of CRC cells and promoted biochemical changes
to MET with a planar cell surface and suppressed formation of CSC, and this was accompanied
by a marked increase in apoptosis. Moreover, to show the anti-cancer impacts of resveratrol and
anti-TNF-βR, we performed MTT and migration assays to determine the optimal suppression rate
and cytotoxicity in all three CRC cell lines. In addition, pro-inflammatory cytokines have been
noted to be synthesized through activated inflammatory cells, like macrophages in the tumor
microenvironment [61], and during this process, the master pro-inflammatory transcription factor,
NF-κB, is a major downstream target of cytokines, and NF-κB is a dominant agent for inducing and
activating many tumor cells [62]. Furthermore, previous studies reported that the NF-κB signaling
pathway was critical to cytokine-promoted migration and EMT in cancer cells [50,63]. Here, we showed
that NF-κB is a crucial downstream target of TNF-β signaling and that it is a transcription regulator
of TNF-β-induced FAK activation. Therefore, we used agents that block TNF-β-promoted NF-κB
signaling, such as resveratrol. We have shown that resveratrol down-modulated TNF-β-activated
NF-κB and NF-κB-promoted proteins, which are involved in invasion (MMPs), metastasis (CXCR4),
and proliferation (Ki-67) in CRC cell lines. Indeed, these results are also consistent with those that
have shown that resveratrol is a potent multitargeting anti-tumor agent and this effect is mediated
partially through inhibiting NF-κB and NF-κB-promoted proteins in different tumor cells [13,30,54,64].
Interestingly, it has been shown previously, that the subcellular main target Sirt-1 protein for resveratrol
is associated with NF-κB, and that Sirt-1 is able to deacetylate NF-κB on lysine 310, thus modulating
NF-κB transcriptional activity [54,65].
We also showed that resveratrol induced nucleus pyknosis, chromatin condensation,
and apoptotic body generation, indicating that resveratrol activated caspase-dependent cell death
in CRC cells, which is in correlation with previous studies [32,54], highlighting how the resveratrol
signaling pathway acts as an anti-tumor agent in CRC cells in a cytokine-promoted microenvironment.
It has been reported, that TNF-α as an activator and modulator of tumorigenesis induces the
invasion abilities of tumor cells [61,66], but very little data is available regarding the impacts of
TNF-β/TNF-βR on promoting tumor cell migration and EMT. In the present report, we demonstrated
by immunoprecipitation assay that the impact of TNF-β-promoted CRC cell invasion and EMT points
to a functional connection between TNF-βR and tumor-inducing biomarkers, such as FAK and NF-κB,
suggesting that TNF-β increased the expression of TNF-βR, leading to FAK and NF-κB activation.
When the TNF-βR pathway was suppressed by its specific antibody, the TNF-β/TNF-βR pathway
appeared to lose its supporting role in CRC cell proliferation and migration. Our findings show that
FAK is an intracellular molecular target of TNF-βR and, thus, tumor cell invasion. Indeed, it has been
previously shown that FAK is significantly up-regulated in many cancer cells [30,67], involved in tumor
cell survival, proliferation, and invasion [68], and that resveratrol clearly down-modulates cancer cell
migration, viability, clonogenicity, and growth by suppression of FAK phosphorylation in CRC cells and
other cancers [30,69–71]. The specific motility of cells is organized by polymerization and cross-linking
of cytoskeleton proteins, like actin filaments conducting the formation of filopodia and lamellipodia,
and they are stabilized through FAK during tumor cell migration [72,73]. Indeed, our findings
provide insight into the determining role of TNF-β for EMT and tumor invasion in different CRC cells.
These findings underline the significance of targeting TNF-β, and therefore, suppressing EMT and
CSCs may be a promising approach to inhibiting the metastasis of tumor cells.
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These data suggest for the first time the impact of TNF-βR on CRC cell EMT and migration,
and underlines an important functional coherence between TNF-βR and cancer-stimulating factors,
such as FAK, NF-κB, and NF-κB-related proteins.
5. Conclusions
This report examined the down-regulatory effects of resveratrol on TNF-β as a potent
inflammatory cytokine, activating EMT in three CRC cell lines. Resveratrol, like anti-TNF-βR,
significantly suppressed the TNF-β-induced EMT, EMT-associated factors, CSC formation,
and migration of CRC cell lines. We found that TNF-β-promoted TNF-βR physically formed a protein
complex with FAK and NF-κB and that these could be upregulated by TNF-β. More interestingly, this is
the first study to indicate that FAK and NF-κB serve as a subcellular molecular downstream target
of TNF-βR (Figure 7). Thus, our results present important evidence and data for future basic science
investigations and clinical trials aiming to investigate the role of TNF-β/TNF-βR and resveratrol that
will enable the development of a potential novel therapeutic strategy for CRC.Nutrients 2019, 11, x FOR PEER REVIEW 16 of 19 
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